Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cytopia
Richmond (Melbourne), Victoria, Australiacytopia.com.au ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cytopia developed novel small molecules, including a vascular disrupting agent (VDA) CYT997 (phase 2 for cancer) and JAK2 inhibitor CYT387 (ready for phase 1 in myeloproliferative disorders at the time of acquisition). Clinical results showed activity in solid tumors; further data post-acquisition resided with the acquirer[1][2][3][4].
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Novartis (collaboration: Novartis handled product development and commercialization for select programs; Cytopia retained co-promotion rights in Australia/New Zealand)[7]Cancer Therapeutics CRC Pty Ltd (academic/commercial consortium collaboration)[3]
Beyond the preview
Go deeper on Cytopia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytopia.